Meeting Banner
Abstract #3174

Macromolecular Versus Small Molecular MRI Contrast Media for Monitoring Anti-Angiogenic Drug Effect of Bevacizumab on Experimental Human Breast Cancer Xenografts

Clemens C. Cyran1,2, Yanjun Fu2, Victor Rogut2, Bundit Chaopathomkul2, David M. Shames2, Michael F. Wendland2, Robert C. Brasch2

1Department of Clinical Radiology, University Hospitals Munich - Grosshadern, Munich, Germany; 2Radiology, University of California San Francisco, San Francisco, CA, USA

The macromolecular contrast media (MMCM) albumin-(Gd-DTPA) 27 was compared to the small molecular contrast media (SMCM) Gd-DTPA for their suitability to monitor early anti-angiogenic effect of bevacizumab on human breast cancer xenografts in dynamic MRI assays of endothelial permeability in a tandem experiment. Rats were imaged at baseline and 24h after intraperitoneal bevacizumab application. MRI assays of tumor endothelial permeability revealed a significant decrease of endothelial permeability using albumin-(Gd-DTPA) 27 whereas no significant effect was detected using Gd-DTPA. The MMCM albumin-(Gd-DTPA) 27 proved to be superior to the SMCM Gd-DTPA for the detection of early anti-angiogenic effect of bevacizumab.